ABSTRACT
Introduction Quality of life has become an increasingly important concern in clinical decision-making for patients with prostate cancer. With the advent of screening programs utilizing serum prostate-specific antigen (PSA) testing, prostate cancer appears to be diagnosed at an earlier stage than in the pre-PSA era. Whether early treatment has translated into improved survival rates or has increased the burden of treatment of clinically-insignificant cancers is debatable. What is certain, however, is that due to this stage migration, more patients are treated for prostate cancer and are thus living longer with their disease.1
